Independent and reader-supportedScoring method is publicNo program with an FDA warning letter is rankedUpdated November 17, 2026

GLP-1 nausea: what helps, and when to call your clinician

By the RadarGLP1 editorial teamUpdated November 17, 2026Fact-checked against the sources listed below

Nausea is one of the most common side effects of GLP-1 medications, especially in the first weeks and after each dose increase. For many people it eases with time. Here is what helps, and when nausea is a reason to call your clinician.

Why GLP-1s can make you feel sick

GLP-1 medications slow down how fast your stomach empties and act on the parts of the brain that control appetite. That is part of how they work, but it also means food stays in your stomach longer, which can cause nausea, fullness, burping or vomiting. In the clinical trials behind the prescribing information, stomach side effects were most common while the dose was being increased.

What helps

When to call your clinician

Call your prescriber, or seek urgent care, if you have:

The prescribing information for each GLP-1 lists these and other warnings. Read the Medication Guide that comes with your prescription.

Does nausea mean the medication is working?

Not necessarily. Feeling full sooner is expected, but strong nausea is a side effect, not a goal. Many people lose weight with little or no nausea. If you are struggling to eat enough protein or drink enough fluids, tell your clinician.

Does your program help with side effects?

Good follow-up makes the first weeks easier. In our ranking, Noom Med includes unlimited clinician visits and a care team for side effects, and WeightWatchers Med+ has side-effect logging and a care team. See how every program scores on medical follow-up in our ranking of online GLP-1 programs.

Also useful: our protein calculator, because eating enough protein can be harder when you feel queasy.

Sources

  1. Wegovy (semaglutide) prescribing information and Medication Guide, FDA label 2026
  2. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Obesity, 2025
  3. Full text of the joint advisory (PubMed Central)

Keep reading